



Dear Sir/Dear Madam,

We are reaching out today on behalf of Lundbeck Canada to share an important update on our ongoing drug shortage affecting SABRIL® (vigabatrin), indicated for the adjunctive management of partial epilepsies and the management of infantile spasms.

While you may have been made aware of this in recent days via Health Canada's drug shortages website, or via your own physician or pharmacist, we wanted to make sure that we continue to provide our valued stakeholders with up-to-date and accurate information regarding treatment availability.

In August 2022, we shared that we were experiencing a shortage in the 500mg powder for oral solution presentation. This has now been resolved and **SABRIL powder for oral solution is back in stock and available.**

As of March 2023, **we are now reporting a shortage of 500mg SABRIL tablets.** The shortage only affects SABRIL tablets; stock of SABRIL 500mg powder for oral solution is available.

This shortage is due to unexpected drug manufacturing and supply chain disruptions and is effective immediately. At this time, it is unknown when the tablet formulation will be back in stock. Upon learning of the anticipated shortage, Lundbeck Canada informed Health Canada, as well as healthcare professionals and pharmacies.

At Lundbeck, we understand how important it is for patients to have access to the medications they need. For patients and their families, we know there may be questions and concerns. We encourage all patients currently taking SABRIL tablets to consult with their healthcare professional, who can make a decision about their treatment plan.

Lundbeck remains committed to Canada's epilepsy community and wants to reassure you that we are working diligently to solve this issue and ensure that supply of SABRIL – in any form – remains available for patients.

If you have any further questions, please feel free to reach out to us at any time. If your questions are medical in nature, please contact your healthcare professional. For questions about the product itself, please see the [Canadian SABRIL monograph](#) for complete product information or contact Lundbeck Canada Medical Information at 1-866-880-4636 or [canadamedicalinformation@lundbeck.com](mailto:canadamedicalinformation@lundbeck.com).

Regards,

Fakher Aissa  
Vice President, Market Access & Public Affairs  
Lundbeck Canada

Martine Hubert, MD  
Vice President, Medical and Regulatory Affairs  
Lundbeck Canada Inc.